DALLAS, Aug. 13, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Nabi Biopharmaceuticals (Nasdaq:NABI). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Nabi Biopharmaceuticals (Nasdaq:NABI) should be of particular interest to biopharmaceutical companies: Baxter International Inc. (NYSE:BAX), Amgen Inc. (Nasdaq:AMGN), Genzyme Corp. (Nasdaq:GENZ) and Wyeth (NYSE:WYE).
It is available at: http://www.stockpreacher.com/n/NABI/
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Nabi Biopharmaceuticals (NABI) develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The Company's products in development includes NicVAX, (Nicotine Conjugate Vaccine), a proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse; and PentaStaph (Pentavalent S.aureus Vaccine), a pentavalent vaccine designed to prevent S.aureus infections, including those infections caused by antibiotic-resistant strains of S.aureus.
In the report, the analyst notes:
"The Company has a manufacturing services agreement with Biotest Pharmaceuticals Corp., which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. NABI also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and the University of Maryland.
"In August NABI sold its staph infection vaccine PentaStaph to GlaxoSmithKline PLC in a deal worth as much as $46 million. NABI will receive $20 million upfront, with the rest of the payments depending on four undisclosed milestones being accomplished. It said it expects the sale to close by the end of the year, and said it believes it will complete the four milestones within 18 months. Staph infections are caused by a drug-resistant strain of bacteria often found in hospitals. PentaStaph is being tested against three different strains of staph and two other antigens."
To read the entire report visit: http://www.stockpreacher.com/n/NABI/
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
CONTACT: StockPreacher.com
Jeff Bishop
(469)-252-3505
press@beaconequity.com
